Hypercholesterolemia - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H1 2018’, provides an overview of the Hypercholesterolemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia

- The report reviews pipeline therapeutics for Hypercholesterolemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hypercholesterolemia therapeutics and enlists all their major and minor projects

- The report assesses Hypercholesterolemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hypercholesterolemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AFFiRiS AG

Akcea Therapeutics Inc

AstraZeneca Plc

BioLingus AG

Catabasis Pharmaceuticals Inc

Chong Kun Dang Pharmaceutical Corp

CymaBay Therapeutics Inc

Daewon Pharm Co Ltd

Daewoong ...

AFFiRiS AG

Akcea Therapeutics Inc

AstraZeneca Plc

BioLingus AG

Catabasis Pharmaceuticals Inc

Chong Kun Dang Pharmaceutical Corp

CymaBay Therapeutics Inc

Daewon Pharm Co Ltd

Daewoong Co Ltd

Dicerna Pharmaceuticals Inc

Dybly AG

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Golden Biotechnology Corp

Immune Response BioPharma Inc

Innovent Biologics Inc

Kadmon Corp LLC

Kyorin Pharmaceutical Co Ltd

Leading BioSciences Inc

LipimetiX Development Inc

Madrigal Pharmaceuticals Inc

Medlab Clinical Ltd

Noxopharm Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Progenra Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen HighTide Biopharmaceutical Ltd

The Medicines Company

Viking Therapeutics Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia – Overview 6

Hypercholesterolemia – Therapeutics Development 7

Hypercholesterolemia – Therapeutics Assessment 18

Hypercholesterolemia – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia – Overview 6

Hypercholesterolemia – Therapeutics Development 7

Hypercholesterolemia – Therapeutics Assessment 18

Hypercholesterolemia – Companies Involved in Therapeutics Development 26

Hypercholesterolemia – Drug Profiles 42

Hypercholesterolemia – Dormant Projects 175

Hypercholesterolemia – Discontinued Products 181

Hypercholesterolemia – Product Development Milestones 183

Appendix 196

List of Tables

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hypercholesterolemia – Pipeline by AFFiRiS AG, H1 2018

Hypercholesterolemia – Pipeline by Akcea Therapeutics Inc, H1 2018

Hypercholesterolemia – Pipeline by AstraZeneca Plc, H1 2018

Hypercholesterolemia – Pipeline by BioLingus AG, H1 2018

Hypercholesterolemia – Pipeline by Catabasis Pharmaceuticals Inc, H1 2018

Hypercholesterolemia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Hypercholesterolemia – Pipeline by CymaBay Therapeutics Inc, H1 2018

Hypercholesterolemia – Pipeline by Daewon Pharm Co Ltd, H1 2018

Hypercholesterolemia – Pipeline by Daewoong Co Ltd, H1 2018

Hypercholesterolemia – Pipeline by Dicerna Pharmaceuticals Inc, H1 2018

Hypercholesterolemia – Pipeline by Dybly AG, H1 2018

Hypercholesterolemia – Pipeline by Esperion Therapeutics Inc, H1 2018

Hypercholesterolemia – Pipeline by Gemphire Therapeutics Inc, H1 2018

Hypercholesterolemia – Pipeline by Golden Biotechnology Corp, H1 2018

Hypercholesterolemia – Pipeline by Immune Response BioPharma Inc, H1 2018

Hypercholesterolemia – Pipeline by Innovent Biologics Inc, H1 2018

Hypercholesterolemia – Pipeline by Kadmon Corp LLC, H1 2018

Hypercholesterolemia – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Hypercholesterolemia – Pipeline by Leading BioSciences Inc, H1 2018

Hypercholesterolemia – Pipeline by LipimetiX Development Inc, H1 2018

Hypercholesterolemia – Pipeline by Madrigal Pharmaceuticals Inc, H1 2018

Hypercholesterolemia – Pipeline by Medlab Clinical Ltd, H1 2018

Hypercholesterolemia – Pipeline by Noxopharm Ltd, H1 2018

Hypercholesterolemia – Pipeline by Pfizer Inc, H1 2018

Hypercholesterolemia – Pipeline by Portola Pharmaceuticals Inc, H1 2018

Hypercholesterolemia – Pipeline by Progenra Inc, H1 2018

Hypercholesterolemia – Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Hypercholesterolemia – Pipeline by RegenxBio Inc, H1 2018

Hypercholesterolemia – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Hypercholesterolemia – Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2018

Hypercholesterolemia – Pipeline by The Medicines Company, H1 2018

Hypercholesterolemia – Pipeline by Viking Therapeutics Inc, H1 2018

Hypercholesterolemia – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018

Hypercholesterolemia – Dormant Projects, H1 2018

Hypercholesterolemia – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hypercholesterolemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Hypercholesterolemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports